Incyte Corporation: Data Presented at the 30th San Antonio Breast Cancer Symposium Supports Further Development of INCB7839 as a New Oral Treatment for Breast Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced today that three scientific posters have been presented at the 30th San Antonio Breast Cancer Symposium describing the potential benefits of its selective sheddase inhibitor, INCB7839, in the treatment of metastatic breast cancer.